Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People who are willing to take part and able to sign a consent form
• People expected to live for at least 12 weeks
• People who are generally well enough to carry out light activity or desk work (a doctor will assess this using a standard scale)
• People whose liver cancer has been confirmed by tissue testing (biopsy)
• People for whom surgery or local treatments are not expected to be helpful, as assessed by the trial doctors
• People whose cancer has continued to grow after at least one previous course of cancer treatment, and for whom standard treatment options are not expected to offer much benefit
• People whose tumour tissue (either fresh or preserved) tests strongly positive for a protein called GPC-3
• People who have at least one tumour that can be measured on a scan, according to standard guidelines
• People with lung spread of cancer that is considered manageable
• People with a specific stage of liver cancer (BCLC stage B or C) and acceptable liver function (a doctor will assess this)
• People without active hepatitis B virus infection
• People with adequate organ function (a doctor will assess this through blood tests)
• People with suitable veins for a blood collection procedure
• People whose side effects from previous treatments have mostly resolved, with the exception of hair loss or nerve-related symptoms
• Women who could become pregnant must agree to use reliable contraception from 28 days before a preparation treatment through to one year after the cell infusion; men who have not had a vasectomy and are sexually active with women who could become pregnant must agree to use barrier contraception from the preparation treatment through to one year after, and must not donate sperm during the study
• Women who could become pregnant must have a negative pregnancy blood test at the start of the study and again 48 hours before a preparation treatment

Who may not be able to join:

• People with a type of liver cancer called cholangiocarcinoma, or a mixed type combining liver and bile duct cancer
• People with active cancer spread to the brain
• People whose largest tumour measures 15 cm or more across, or who have other factors the investigator considers a risk
• People who have had another separate cancer diagnosed within the past 3 years (some exceptions may apply for certain fully removed early-stage cancers — confirm with trial site)
• People with ongoing autoimmune conditions requiring long-term use of immune-suppressing medicines
• People who have previously received genetically modified T-cell therapies (such as CAR-T or TCR-T) or similar treatments
• People with active hepatitis C, HIV, or syphilis
• People who have had an organ transplant
• People with an uncontrolled or active infection at certain points during the trial process
• People with serious heart or cardiovascular disease
• People with a significant history or current condition affecting the brain or nervous system
• People currently experiencing a complication of liver disease called hepatic encephalopathy (a condition affecting brain function)
• People who have had significant bleeding within 30 days before the trial, or who need long-term blood-thinning medication
• People who have had an active stomach or intestinal ulcer, or gastrointestinal bleeding, within the past 3 months
• Women who are pregnant or breastfeeding
• People who have not completed the required waiting period after previous treatments before the blood collection procedure (confirm details with trial site)
• People who are unable or unwilling to follow the trial procedures, as assessed by the trial doctors
• People the investigators consider unsuitable for other reasons
• People who have previously had an allergic reaction or serious intolerance to the trial treatment or its components

Important: Always verify eligibility with the trial site directly before applying.